Fibrinogenemia Tampere - A dysfibrinogenemia with defective gelation and thromboembolic disease

Thrombosis Research

Volumn 78, Issue 4, 1995, Pages 323-339

  Hessel, Birgit ^a   Silveira, Angela M V ^a   Carlsson, Kjell ^b   Oksa, Heikki ^c   Rasi, Vesa ^d   Vahtera, Elina ^c   Procyk, Roman ^e   Blombäck, Birger ^a,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d FINNISH RED CROSS BLOOD SERVICE   (Finland)

^e NEW YORK BLOOD CENTER   (United States)

Author keywords

Dysfibrinogenemia; polymerization; thrombotic disease

Indexed keywords

BATROXOBIN; CALCIUM; HIRUDIN; THROMBIN;

ARTICLE; BLOOD CLOTTING TIME; CASE REPORT; DYSFIBRINOGENEMIA; FEMALE; HUMAN; POLYMERIZATION; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADULT; CASE REPORT; FEMALE; FIBRIN; FIBRINOGENS, ABNORMAL; HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; SUPPORT, NON-U.S. GOV'T; THROMBOEMBOLISM;

EID: 0028917650     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(95)00065-Y     Document Type: Article

References (41)

1. Molecular and genetic abnormalities of fibrinogen
2. Abnormal Fibrinogens: The present status of structure elucidation
3. Fibrinogen and fibrin formation and its role in fibrinolysis
4. Structure abnormality of fibrinogen Metz and its relationship to the clotting defect
5. Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-Aα16 by a histidyl residue
6. Fibrinogen Aarhus — A new case of dysfibrinogenemia
7. Fibrinogen Aarhus: An abnormal fibrinogen with Aα 19Arg-〉Gly substitution
8. Characterization of an abnormal fibrinogen Osaka V with the replacement of γ-Arginine 375 by Glycine. The lack of high affinity calcium binding to D-domains and the lack of protective effect of calcium on fibrinolysis
9. Fibrinogen Baltimore IV: congenital dysfibrinogenemia with a γ275(Arg-〉Gly) substitution
10. Fibrinogen Detroit — A molecular defect in the N-terminal disulphide knot of human fibrinogen?
11. The polymerization of fibrin prepared from fibrinogen Haifa (γ275Arg-〉His)
12. 1 by plasmin and the generation of a new plasmin cleavage site
13. Hereditary dysfibrinogenemia in a patient with thrombotic disease
14. Characterization of fibrinogen New York 1. Dysfunctional fibrinogen with a deletion of Bβ(9–72) corresponding exactly to exon 2 of the gene
15. A new type of congenital dysfibrinogenaemia with defective fibrin lysis — Dusard syndrome: possible relation to thrombosis
16. Fibrinogen Bern I: A hereditary fibrinogen variant with defective conformational stabilization by calcium ions
17. Dysfibrinogenemia associated with thrombosis and third trimester fetal loss. A case report
18. Native fibrin gel networks and factors influencing their formation in health and disease
19. Production, evaluation, and properties of α-thrombin
20. Fibrinoligase. The fibrin stabilizing factor system
21. Fibrin-stabilizing factor (Factor XIII)
22. FXIII induced gelation of human fibrinogen — An alternative thiol enhanced, thrombin independent pathway
23. Fibrinase. I. Purification of substrate and enzyme
24. New methods for determination of fibrinogen, fibronectin and factor XIII
25. Factor XIII catalyzed formation of fibrinogen-fibronectin oligomers - a thiol enhanced process
26. Purification of human and bovine fibrinogen
27. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
28. The binding of calcium to bovine fibrinogen
29. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity
30. Fibrinogen Aarhus and factor XIII induced polymerization and gel formation
31. Dysfibrinogenemia (Fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation
32. The reliability of molecular weight determinations by dodecyl sulphate — polyacrylamide gel electro-phoresis
33. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study
34. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men
35. Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation
36. Fibrin gel characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis
37. Calcium and fibrin gel structure
38. Fibrinogen Bern I: substitution γ337 Asn-〉Lys is responsible for defective fibrin monomer polymerization
39. Dusart syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure
40. The effect of fibrin structure on fibrinolysis